603-84-9

Basic information

• Product Name: 2-chloro-3-nitro-phenol
• Synonyms: 2-chloro-3-nitro-phenol;Phenol, 2-chloro-3-nitro-;2-Chlor-3-nitro-1-hydroxy-benzol;3-hydroxy-2-chloronitrobenzene;2-Chlor-3-nitrophenol
• CAS NO: 603-84-9
• Molecular Formula: C₆H₄ClNO₃
• Molecular Weight: 173.55
• Product Categories: API intermediates;Chlorine Compounds;Nitro Compounds
• Mol File: 603-84-9.mol
• Article Data: 11

Chemical Properties

• Melting Point: 120.5 °C
• Boiling Point: 279.6 °C at 760 mmHg
• Flash Point: 122.9 °C
• Appearance: Orange crystalline powder
• Density: 1.554 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.627
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 7.39±0.25(Predicted)
• CAS DataBase Reference: 2-chloro-3-nitro-phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-3-nitro-phenol(603-84-9)
• EPA Substance Registry System: 2-chloro-3-nitro-phenol(603-84-9)

Safety Data

• Hazardous Substances Data: 603-84-9(Hazardous Substances Data)

Usage

General Description

2-chloro-3-nitro-phenol is a chemical compound with the molecular formula C6H4ClNO3. It is a pale yellow solid that is commonly used as an intermediate in the production of pharmaceuticals, dyes, and pesticides. 2-chloro-3-nitro-phenol is classified as a chlorinated nitrophenol, and is known to be toxic and harmful if ingested, inhaled or absorbed through the skin. 2-chloro-3-nitro-phenol is also considered to be harmful to the environment, as it can be hazardous to aquatic organisms and may persist in the environment for a long time. Therefore, proper handling and disposal of this chemical compound is essential to minimize its potential impact on human health and the environment.

InChI:InChI=1/C6H4ClNO3/c7-6-4(8(10)11)2-1-3-5(6)9/h1-3,9H

Upstream product

• 3970-39-6 2-chloro-3-methoxynitrobenzene 
• 99-09-2 3-nitro-aniline 
• 121-88-0 5-Nitro-2-aminophenol 
• 603-85-0 2-Amino-3-nitrophenol 
• 62153-30-4 acetic acid-(4-methoxy-2,3-dinitro-anilide) 
• 861086-17-1 acetic acid-(4-ethoxy-3-chloro-2-nitro-anilide) 
• 5473-00-7 4-methoxy-2,3-dinitro-aniline 
• 858855-42-2 4-ethoxy-3-chloro-2-nitro-aniline 
• 885-81-4 N-(4-ethoxy-2-nitrophenyl)acetamide 
• 16554-45-3 2-methoxy-6-nitroaniline 
• 16315-07-4 2,3-dinitroanisole 
• 62-44-2 4-ethoxyacetanilide 
• 554-84-7 meta-nitrophenol 
• 7782-50-5 chlorine 

Downstream Products

• 16762-86-0 2-Chlor-1-nitro-3-isopropyloxy-benzol 
• 3926-65-6 2-Chlor-6-hydroxy-10-(3-dimethylamino-propyl)-phenthiazin 
• 16762-88-2 4-Chlor-2-brom-2'-nitro-6'-isopropyloxy-diphenylsulfid 
• 80117-38-0 2-chloro-1-nitro-3-phenylmethoxybenzene 
• 1336964-16-9 2-chloro-3-[(1-methylethyl)oxy]aniline 
• 163120-56-7 1-(2-chloro-3-nitrophenoxy)propan-2-amine 
• 122484-85-9 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-5-oxo-1H-1,4-diazepin-1-yl)-6-phenylmethoxy-1H-benzimidazole 
• 122484-84-8 1-(2-ethoxyethyl)-2-(hexahydro-5-oxo-1H-1,4-diazepin-1-yl)-6-phenylmethoxy-1H-benzimidazole 
• 122484-82-6 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-7-phenylmethoxy-1H-benzimidazole 
• 122484-91-7 (2-Benzyloxy-6-nitro-phenyl)-(2-ethoxy-ethyl)-amine 

Relevant articles and documents

TRPV4 ANTAGONISTS

The present invention relates to quinoline analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

HEPATITIS C INHIBITOR DIPEPTIDE ANALOGS

The present invention relates to compounds of formula (I): wherein R1, R2, R4, n and m are as defined herein and R3 is selected from: (i) -C(O)OR31 wherein R31 is (C1-6)alkyl or aryl, wherein the (C1-6)alkyl is optionally substituted with one to three halogen substituents; (ii) -C(O)NR32R33, wherein R32 and R33 are each independently selected form H, (C1-6)alkyl, and Het; (iii) -SOvR34, wherein v is 1 or 2 and R34 is selected from: (C1-6)alkyl, aryl, Het, and NR32R33 wherein R32 and R33 are as defined above; and (iv) -CO(O)-R35, wherein R35 is selected from (C1-8)alkyl, (C3-7)cycloalkyl-(C1-4)alkyl, aryl, aryl-(C1-6)alkyl, Het and Het-(C1-6)alkyl, each of which are optionally substituted with one or more substituents each independently selected from halo, (C1-6)alkyl, (C3-7)cycloalkyl, aryl, Het, hydroxyl, -O-(C1-6)alkyl, -S-(C1-6)alkyl, -SO-(C1-6)alkyl, -SO2-(C1-6)alkyl, -O-aryl, -S-aryl, -SO-aryl and -SO2-aryl, wherein the aryl portion of the -O-aryl, -S-aryl, -SO-aryl and -SO2-aryl are each optionally substituted with one to five halo substituents. The present invention further relates to pharmaceutical compositions containing the compounds of formula (I) and methods for using these analogs in the treatment of HCV infection.

Hepatitis C inhibitor peptide analogs

Compounds of formula (I): wherein R1, R2, R3, R4, R5, Y, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.